India High Court Orders Cipla To Prove Drug No Tarceva Infringement
This article was originally published in PharmAsia News
India's Delhi high court ordered Cipla to show its generic is not an infringement on the Roche patent for its Tarceva (erlotinib) drug for treating lung cancer.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.